Here we report the characterization of AtMYB118, a gene encoding a putative R2R3-type MYB transcription factor, which expresses
predominantly in siliques. Real-time quantitative PCR analysis and in situ hybridization showed that the transcripts of AtMYB118 were mainly detected in developing embryos. Constitutive over-expression of AtMYB118 resulted in pleiotropic phenotypes, including dwarfism, compact rosettes, backward curly-leaves, smaller flowers and siliques, and premature seed dehydration at the tip of siliques. Microarray analysis showed that many genes encoding proteins accumulated during embryogenesis were remarkably up-regulated in AtMYB118-over-expressed transgenic plants, including late embryogenesis Saracatinib cost abundant proteins (LEA proteins), storage proteins, seed maturation proteins, and proteins related with seed dehydration, desiccation and ABA signaling pathway.
These results suggest that AtMYB118 may play an important selleck compound role during embryogenesis and seed maturation.”
“In the title compound, C13H16ClFN2O, the piperazine ring is flanked by 1-(2-fluorobenzyl) piperazine and adopts a chair conformation. The dihedral angle between the fluorophenyl ring and the four planar C atoms (r.m.s. = 0.0055 angstrom) of the piperazine chair is 78.27 (7)degrees, whereas the dihedral angle between the four planar C atoms of the piperazine chair and the ethanone plane is 55.21 (9) angstrom; the Cl atom displaced by 1.589 (2) angstrom out of the plane.”
“Due to the increasing incidence of Alzheimer’s disease (AD), many studies have aimed to improve its diagnosis. Particular attention has been focused on measuring volumes of brain structures. Only few studies have investigated-whether the cerebellar volume changes with the stage of dementia. It is controversial whether the serum
apolipoprotein E (ApoE) level is an appropriate AD marker. This study ASP2215 was designed to clarify the significance of both cerebellar volume measurements and ApoE level measurements as markers of neurodegenerative changes.\n\nThis study included 55 subjects with AD, 30 subjects with mild cognitive impairments (MCI), and a control group with 30 subjects. We measured the brain, cerebellum, and brain stem volumes with magnetic resonance imaging (MRI). We determined serum ApoE levels, APOE genotypes, and neuropsychological test scores.\n\nIn the control group, we found that ApoE levels were significantly higher for subjects with the APOE 2/3 genotype than those with the 4/4 genotype. This finding may indicate that ApoE plays a protective role against AD development in subjects with the APOE 2/3 genotype. ApoE levels were not significantly different in patients with AD and MCI. No correlations were found between serum ApoE levels and Mini-Mental State Examination (MMSE) scores or the volumes of brain structures.\n\nThis study could not confirm the appropriateness of the cerebellum volume as an early AD marker.